Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

BACKGROUND: Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice. This study aimed to investigate the comparative cardiovascular safety of GLP-1ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chun-Ting, Yang, Chen-Yi, Ou, Huang-Tz, Kuo, Shihchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293792/
https://www.ncbi.nlm.nih.gov/pubmed/32534570
http://dx.doi.org/10.1186/s12933-020-01053-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293792/
https://www.ncbi.nlm.nih.gov/pubmed/32534570
http://dx.doi.org/10.1186/s12933-020-01053-0

Ejemplares similares